Mike Dybbs, PhD


Mike Dybbs has been Partner at Samsara since the fund was launched in 2017. He currently serves on the board of a number of Samsara portfolio companies, including: Delfi Diagnostics, Enara Bio, Fluent, Ionpath, Nkarta Therapeutics (NKTX) and Sutro (STRO).

Prior to Samsara, Mike was a Partner at New Leaf Venture Partners, where he served on the boards of Versartis (VSAR), Dimension Therapeutics (DMTX), Advanced Cell Diagnostics (acquired by Bio-Techne) and Principia (PRNB, acquired by Sanofi). Before joining New Leaf, Mike was a Principal at the Boston Consulting Group, where he was a core member of their health care practice.

Mike received an A.B. in biochemical sciences from Harvard and a PhD in molecular biology from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His research was published in peer-reviewed journals, including Nature, Science, and Neuron.